[
  {
    "ts": null,
    "headline": "Investors load Corxel with $287M for a ‘differentiated’ obesity pill",
    "summary": "The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.",
    "url": "https://finnhub.io/api/news?id=e15687b3e8e24a1ac7f5b2e34f42ec5fc7090b2872536bb43c1f1fba6460dfe1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769090400,
      "headline": "Investors load Corxel with $287M for a ‘differentiated’ obesity pill",
      "id": 138207091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.",
      "url": "https://finnhub.io/api/news?id=e15687b3e8e24a1ac7f5b2e34f42ec5fc7090b2872536bb43c1f1fba6460dfe1"
    }
  }
]